Hypertension

Latest News


CME Content


It is well established that among patients with the clinical syndrome of heart failure, approximately half have preserved systolic function, known commonly as heart failure with preserved ejection fraction (HFpEF). Although originally considered to be a syndrome that pathophysiologically involves diastolic dysfunction, ongoing investigation suggests that although diastolic abnormalities may be present in many patients, other aspects of pathophysiology likely also contribute to symptoms. This study examined the association of beta-blockers with mortality in patients with HFpEF.

The US Food and Drug Administration (FDA) has approved a polypill for hypertension, a combination of perindopril arginine and amlodipine (Prestalia/ Symplmed Pharma-Servier).

A 35 year-old man with a history of hypertension, obstructive sleep apnea and obesity presents to clinic with complaints of non-cardiac chest discomfort. He is requesting refills of his blood pressure medications. His insurance changed 6 months ago and he has not had them since. The nurse performs the intake vital signs and reports that the patient has a blood pressure of 280/150 mmHg.

The most common cause of sudden cardiac death in young people is hypertrophic cardiomyopathy, an inherited condition that can lead to heart failure, angina, arrhythmia and sudden cardiac death. There is no medical treatment shown to halt or reverse the progression of the disease-just palliative care or surgery.

In older adults, mild control of systolic pressure is good enough, an Oregon research team has found. Writing in Drugs & Aging, Leah Goeres and colleagues at the College of Pharmacy at Oregon State University and Oregon Health & Science University said that for adults age 60 and over, said a reading of 150 for systolic blood pressure (SPB) is adequate-upsetting the conventional wisdom that these patients should get enough medications or other treatments to bring SPB down to 140.

The American Society of Hypertension (ASH) is the largest US professional organization dedicated to eradicating hypertension and its consequences. The following study presentations were highlights of the organization's 29th annual meeting in New York City.